Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-1-IR800 (also known as PSMA-1-IRDye800CW) is a preclinical near-infrared (NIR) fluorescent imaging agent designed for the intraoperative visualization and fluorescence-guided surgery of prostate cancer. Developed by researchers at Case Western Reserve University and the Cleveland Clinic, the agent consists of a high-affinity, urea-based peptidomimetic ligand (PSMA-1) conjugated to the near-infrared fluorescent dye IRDye 800CW. PSMA-1-IR800 specifically targets prostate-specific membrane antigen (PSMA), a cell-surface protein highly overexpressed in prostate cancer cells and tumor neovasculature. Upon binding to PSMA, the agent enables real-time, high-contrast fluorescence imaging of tumor margins and metastatic lesions, helping surgeons achieve complete tumor resection while minimizing damage to healthy tissues. Preclinical studies in mouse models have demonstrated excellent tumor accumulation and rapid clearance from non-target tissues, with notably low uptake in salivary glands compared to other PSMA-targeted agents.
| Indication | Highest phase | Status |
|---|---|---|
| prostate cancer and precursor lesions | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: prostate cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PSMA-1-IR800.
Work on PSMA-1-IR800? Claim this page to correct or add information. Claim this page